Company Description
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom.
The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.
It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023.
Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
| Country | United Kingdom |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Stephen A. Stamp |
Contact Details
Address: 1 Caspian Point, Caspian Way Cardiff, X0 CF10 4DQ United Kingdom | |
| Phone | 44 (0)1235 888300 |
| Website | biodexapharma.com |
Stock Details
| Ticker Symbol | BDRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001643918 |
| ISIN Number | US59564R7089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen A. Stamp | Chief Executive Officer, Chief Financial Officer, Company Secretary and Director |
| Dr. Dmitry Zamoryakhin M.D. | Chief Scientific Officer and Chief Medical Officer |
| Dr. Daniel Palmer MBA, Ph.D. | Vice President of Technology |
| Nicola Tuckwell | Vice President and Head of Clinical Operations |
| Fiona Sharp | Group Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | 6-K | Report of foreign issuer |
| Apr 19, 2024 | 6-K | Report of foreign issuer |
| Apr 19, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 28, 2024 | 424B3 | Prospectus |
| Mar 27, 2024 | EFFECT | Notice of Effectiveness |
| Mar 20, 2024 | UPLOAD | Filing |
| Mar 18, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Feb 28, 2024 | 424B3 | Prospectus |
| Feb 28, 2024 | 424B3 | Prospectus |
| Feb 28, 2024 | 424B3 | Prospectus |